Skip to main content
. 2025 Sep 8;12:1639586. doi: 10.3389/fmed.2025.1639586

Table 4.

Patient cohorts’ follow-up characteristics stratified by tertiles of change in the 6-min walk test distance.

Variable Δ 6MWD tertile 1 Δ 6MWD tertile 2 Δ 6MWD tertile 3 p-value
(n = 59) (n = 55) (n = 56)
Δ 6MWD, m, border ≤ − 40 ≤ + 15 > + 15
Time to follow-up, months, median (IQR) 13 (12–15) 12 (8–16) 13 (10–14) 0.534
6MWD, m, mean (SD) 288 (117) 381 (124) 424 (134) <0.001
Δ 6MWD, m, mean (SD) −101 (61) −10 (14) 73 (50) <0.001
Δ 6MWD absolute threshold, n (%) 57 (100%) 2 (3.6%) 0 (0.0%) <0.001
Δ 6MWD, %, mean (SD) −27.8% (16.3%) −2.5% (4.1%) 24.7% (20.3%) <0.001
Δ 6MWD relative threshold, n (%) 57 (100%) 17 (30.9%) 0 (0.0%) <0.001
Primary endpoint, n (%) 18 (31.6%) 16 (29.1%) 4 (7.1%) 0.003
Time to primary endpoint, months, median (IQR) 14.1 (8.9–16.5) 13.0 (9.7–19.5) 8.9 (5.5–11.3) 0.278
NT-proBNP, pg./mL, median (IQR) 2,593 (1633–5,302) 2,546 (1661–4,647) 1,533 (823–2,698) <0.001
Δ NT-proBNP, pg(mL), median (IQR) 67 (−648–1,247) 271 (−250–1,262) −18 (−1,058–295) 0.029
TnT, ng/L, median (IQR) 59.5 (38.0–89.0) 54.5 (33.5–75.0) 43.0 (28.0–54.0) 0.006
Δ TnT, ng/L, median (IQR) 3.0 (−2.0–22.5) 1.0 (−3.0–8.0) −1.0 (−6.0–1.5) 0.011
eGFR, mL/min/1.73 m2, mean ± SD 48.1 ± 19.5 51.1 ± 18.7 59.6 ± 17.7 0.002
Δ eGFR, mL/min/1.73 m2, mean ± SD −4.4 ± 9.8 −3.9 ± 10.4 −3.9 ± 12.6 0.746
NAC, n (%) <0.001
1 23 (41.1%) 21 (40.4%) 38 (67.9%)
2 17 (30.4%) 20 (38.5%) 15 (26.8%)
3 16 (28.6%) 11 (21.2%) 3 (5.4%)
Tafamidis, n (%) 57 (100%) 35 (64.8%) 50 (89.2%) <0.001
Started on tafamidis, n (%) 53 (93.0%) 35 (64.8%) 47 (83.9%) <0.001
Time on tafamidis, months, median (IQR) 11.4 (6.6–13.1) 6.6 (6.0–11.6) 11.3 (6.4–12.9) 0.034
Loop diuretics, n (%) 43 (76.8%) 34 (65.4%) 31 (56.4%) 0.074
Loop diuretic dose, mg/kg, median (IQR) 0.345 (0.000–0.818) 0.278 (0.000–0.893) 0.167 (0.000–0.382) 0.022
Loop diuretic escalation, n (%) 21 (42.0%) 17 (36.2%) 10 (19.2%) 0.045

6MWD indicates 6-min walk test distance; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NAC, United Kingdom National Amyloidosis Centre staging system; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; SD, standard deviation; TnT, troponin T.

Metric data are given as mean ± standard deviation or median (interquartile range), and categorical data as counts (percentage).

p-values derived from the Kruskal–Wallis test for metric and the chi-squared test for binary/categorical variables. Statistically significant p-values <0.05 marked in bold.